BRAFTOVI Combo Nearly Doubles PFS in BRAF V600E mCRC, Trial Shows

Pfizer announced detailed results from Cohort 3 of the Phase 3 BREAKWATER trial showing that the BRAFTOVI (encorafenib) plus cetuximab and FOLFIRI regimen nearly doubled median progression-free survival (PFS) versus the comparator arm—15.2 months versus 8.3 months. The data were presented as a late-breaking oral abstract at ASCO 2026 and published concurrently.

The randomized Cohort 3 analysis demonstrated a 56% reduction in the risk of disease progression or death with the BRAFTOVI combination (hazard ratio 0.44; 95% CI 0.27–0.70; p=0.0002). Updated overall survival (OS) analyses showed a 44% reduction in the risk of death (HR 0.56; 95% CI 0.34–0.94); median OS was not reached in the BRAFTOVI arm versus 20.3 months in the comparator. Cohort 3 had previously met its primary endpoint for objective response rate (ORR).

Safety results were consistent with known profiles: grade ≥3 adverse events occurred in 70.4% of patients on the BRAFTOVI regimen versus 80.9% in the control arm, and the most common events included nausea, diarrhea, vomiting, anemia and neutropenia. Treatment discontinuation due to adverse events was 15.5% in the BRAFTOVI arm versus 10.3% in the comparator. These tolerability metrics will factor into regulatory and payer assessments.

Clinically meaningful benefits in both PFS and OS reinforce the regulatory decisions earlier in 2026 to expand approval for the BRAFTOVI combination in first-line BRAF V600E-mutant metastatic colorectal cancer; the U.S. Food and Drug Administration (FDA) has already granted full approval for the regimen in this indication. The results strengthen the case for the BRAFTOVI regimen as a standard-of-care option in this molecular subgroup.

From a market standpoint, robust Phase-3 data of this nature tend to bolster investor confidence in a company’s oncology franchise and can influence valuation assumptions for future revenue from the indication. Market commentary notes that BREAKWATER’s positive cohort results enhance Pfizer’s oncology investment narrative, while analysts caution that long-term commercial outcomes will depend on labeling, reimbursement, and real-world tolerability. Expect continued attention on Pfizer shares and onkoloji sektörü değerlendirmelerinde bunun yansımalarını görmek.